Share on StockTwits

Foundation Medicine (NYSE:FMI) SVP Jason Ryan unloaded 2,361 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $22.61, for a total transaction of $53,382.21. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Foundation Medicine (NYSE:FMI) traded up 3.82% during mid-day trading on Wednesday, hitting $24.21. The stock had a trading volume of 237,678 shares. Foundation Medicine has a 52 week low of $19.513 and a 52 week high of $45.00. The stock has a 50-day moving average of $23.9 and a 200-day moving average of $28.34. The company’s market cap is $682.5 million.

Foundation Medicine (NYSE:FMI) last announced its earnings results on Wednesday, May 7th. The company reported ($0.44) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.48) by $0.04. The company had revenue of $11.45 million for the quarter, compared to the consensus estimate of $11.33 million. The company’s quarterly revenue was up 120.2% on a year-over-year basis. On average, analysts predict that Foundation Medicine will post $-1.81 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on FMI shares. Analysts at Leerink Swann cut their price target on shares of Foundation Medicine from $36.00 to $33.00 in a research note on Friday, May 9th. Analysts at William Blair initiated coverage on shares of Foundation Medicine in a research note on Thursday, April 17th. They set a “market perform” rating on the stock. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $41.50.

Foundation Medicine, Inc is a commercial-stage company. The Company is focused on fundamentally changing the way patients with cancer are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.